Summary: Studies are reported on the reaction kinetics of the glucose assay according to Trinder which involves the specific oxidation of glucose by glucose oxidase and the determination of the hydrogen peroxide released by means of phenol and 4-aminophenazone in the presence of peroxidase. The results have been used to develop a general kinetic fixed-time method for the analysis of glucose in whole blood and serum. The single reagent method has been adapted to the ENI GEMSAEC centrifugal analyzer and to the Abbott AB A-100 analyzer. The procedures exhibited excellent precision and the results correlated well with those obtained by the hexokinase method. Linearity was achieved from 3 to 64 mmol/1 glucose for the GEMSAEC method, and from 3 to 33 mmol/1 glucose for the ABA-100 method. Reagent or sample blank corrections were not necessary. There were no interferences from various drugs, hemoglobin, bilirubin, or lipemia.
Introduction
Among the many methods for blood or serum glucose determination, the procedures based on the oxidation of glucose by glucose oxidase (EC 1.1. The enzyme is specific for ß-glucose which comprises about 64% of total serum glucose (3) . Since the remaining -glucose is converted to the /3-form by mutarotation, the total glucose content of the sample is covered by that reaction (1) .
The hydrogen peroxide released in the glucose oxidase reaction is commonly determined with peroxidase (EC 1.11.1.7) and a suitable hydrogen donor which is oxidized to a colored compound (1) (2) . In the modification according to Trinder (4) This colometric method so far has been carried out as an end^point or equilibrium procedure. Little effort appears to have been expended on the elaboration of a kinetic procedure which potentially can improve the speed, specifity and simplicity of the assay.
It is well recognized that enzymatic substrate analysis can be based on reaction rate measurements, if the Michaelis constant K m of the enzyme is much greater than the initial substrate concentration (5) . In this case, a reaction obeying pseudo-first order kinetics is obtained which can be easily measured on automated instruments by means of kinetic fixed-time methods (6) . An inspection of the properties of glucose oxidase reveales (7) that this enzyme, due to its high K m -value of about 30-110 mmol/1, is ideally suited for kinetic analysis of glucose.
The present study was undertaken to examine the feasibility of a kinetic procedure for glucose determination with use of the assay according to Trinder. The first step in this treatment was to analyze in detail the kinetics of the reaction system. The results obtained enabled us to develop a general kinetic fixed-time method for routine analysis of blood and serum glucose. The method has been adapted for use with two commercially available automated instruments. Each analytical approach has been characterized with respect to precl· sion, accuracy and susceptibility to interference. Box 51, D-6800 Mannheim 31, Germany. D-glucose, bilirubin and ascorbic acid were purchased from E. Merck, D-6100 Darmstadt, Germany. From the constituents of the test kit "Glucose, GOD/PAP method" a single reagent was prepared which contained phosphate buffer (0.1 mol/I, pH 7.0), phenol (11 mmol/1), 4-amino-phenazone (0.75 mmol/1), glucose-oxidase (έ 13 kU/1), and peroxidase (^ 0.8 kU/1). This reagent was used for both, the kinetic procedures with the GEMSAEC or with the ABA-100 and the manual end-point procedure according to Trinder. It was stable for at least 2 months at 4 °C.
Materials and Methods

Apparatus
Procedures Deproteinization (1) 1.0 ml of uranyl acetate solution was added to 0.1 ml of capillary blood or serum. After careful mixing the suspension was centrifugated for 10 min at 3000 r. p. ni. Aliquots of the supernatant were submitted to the manual endpoint procedure according to Trinder or to the automated kinetic assays. GEMSAEC 50 μΐ of calibration standard (505 μιτιοΐ/ΐ) or deproteinized sample was pipetted into cavity Β of the transfer disc, followed by 150 μΐ of physiological saline diluent; 500 μΐ of reagent was pipetted into cavity C of the transfer disc. The disc was placed into the GEMSAEC analyzer which was operated at a wavelength of 510 nm and at 25 °C. The first absorbance reading was taken 35 s after the start of the run (IR = 10), the second reading 90s later. The sample ring was loaded in the following sequence: position 1, distilled water; position 2, standard; and positions 3-16, control sera and patients' samples. There was no need for sample or reagent blanks. Using native serum as a specimen, the procedure given above was followed. However the volume of calibration standard (5.55 mmol/1) and serum to be pipetted into cavity B of the transfer disc was reduced to 5 μΐ. For the calculation of the results, the computer program TC = 5 was used, which is designed for routine kinetic fixedtime analysis (ElectrorNucleonics Europe, Tramsingel 39, Breda, Holland).
ABA-100
50 μΐ of calibration standard (505 μ mo 1/1) or deproteinized sample and 500 μΐ of reagent were pipetted into the 32-place plastic euvet. Using the light filter 500 nm/600 nm, the first absorbance reading was taken at 20 s after the initiation of the run, and the second reading was taken 300 s later. The incubation temperature was 37 °C. The samples in positions 0-2 were distilled water, the sample in position 3 was the standard, and the samples in positions 4-31 were control sera and patients' specimens. It was not necessary to determine reagent or serum blanks. As with the GEMSAEC procedure the volume of standard (5.55 mmol/1) or samples was reduced to 5 μΐ if native serum was submitted to the assay.
Other procedures
The manual glucose oxidase-based endpoint determinations were carried out as described by Trinder (4). However, 0.2 ml of sample and 2.0 ml of reagent were used. Moreover, the incubation was performed for 35-40 min at 20-25 °C, and the measuring wavelength was Hg 546 nm. The hexokinase (EC 2.7.1.1) method was conducted as described by Bergmeyer et al. (8). The AutoAnalyzer I was operated according to the procedure of Trinder (4), using the test kit "Blood sugar, GOP/PAP method". The erythrocyte hemolysate used for the examination of hemoglobin interference was prepared as reported by Gochman et al. (9) . The content of triglycerides or cholesterol of human sera was determined enzymatically as described previously (10, 11) .
Results and Discussion
Reaction Kinetics Figure 1 represents the time course of the overall reaction of the assay, using a sernilogarithinic plot. In a plot of that kind, first-or pse do-first-order behaviour is indicated by straight lines. The slope of these lines is proportional to the rate constant of the reaction (12).-The Figure demonstrates that the velocity of the reaction is first order overall in glucose concentration. However, the reaction displays a distinct two phase rate characteristic. It passes through a fast period in the beginning, after which it enters into a slower period.
The Figure also shows that the rate constant of the fast early stage of the reaction increases, whereas the length of this stage decreases with increasing glucose oxidase concentration. In contrast, the rate of the second portion of the reaction is not influenced by the concentration of the glucose oxidase enzyme. Figure 2 illustrates that the velocity of this reaction phase can be increased by the addition of mutarotase to the reagent. No changes in the reaction rate are to be observed if the concentration of peroxidase is increased ( fig. 2) . We conclude from these observations that in the initial phase of the reaction, the oxidation of the /3-glucose portion of the sample by glucose oxidase is the rate limiting step of the whole reaction sequence. Because of the high K m -value of the enzyme, the reaction follows pseudo-first order kinetics. After the consumption of 0-glucose, the subsequent formation of this molecule from the α-glucose portion of the sample by spontaneous mutarotation becomes rate-limiting. The exact pseudofirst-order behaviour of this isomerization process has long been recognized (3).
From the foregoing it is evident that the reaction system can be kinetically described as where X denotes α-glucose concentration, Υ 0-glucose concentration, and Ζ hydrogen peroxide concentration, kn, k_j, and k+ 2 are the pseudo-first-order rate constants of the respective reactions. The following differential equations and a conservation equation can be formulated (13): ΔΖ is a linear combination of the initial glucose concentrations Xo and Y 0 . Because Y 0 = KXo, AZ is directly proportional to the total amount of glucose, providing the reading times 1χ and t 2 , the terms k+χ, k^ \ and k+ 2 , resp. a and b are held constant during the measurement. All of these requirements can be easily achieved on automated instruments. Since two moles of Ζ are rapidly converted to one mol of absorbing product (II), the absorbance ehaage measured during any selected fixedtime interval is also a linear function of the initial glucose concentration. For these reasons, the kinetic fixed^time approach could be applied successfully to the assay system.
Characterization of Methods
Linearity
The linearity of the automated methods was checked by measuring a series of aqueous glucose standards which had been prepared using weighed quantities of highpurity Z)-glucose. The results observed with use of the GEMSAEC method are shown in figure 3 . the linearity extended up to a concentration of 64 mmol/1 glucose. The Figure also demonstrates that the sensitivity of the procedure in the normal range was reasonable. The upper limit of linearity for the ABA-100 method was 33 mmol/1 glucose.
Precision
Data on the within-run precision of the present methods are provided in table 1. The results illustrate the good reproducibility of each procedure. D y-to-d y precision was determined by assaying two lots of the control serum "Precilip" (Boehringer Mannheim) during 10 days. The glucose content of this serum was 5.42 or 4.80 mmol/1. We found a coefficient of variation of 2.6% for the GEMSAEC method, and a value of 2.9% for the ABA-100 metiiod, if deproteinized sera were analyzed. Without deproteinization, we obtained CV-valiie$ of 3.4% and 3.2% for the respective method. . . 
Accuracy
The glucose concentration of deproteinized human sera was determined by the automated kinetic methods and, in parallel, by the manual hexokinase reference method (8). The results of these correlation studies were excellent ( fig. 4 and 5) . Likewise satisfactory linear regression parameters were obtained if capillary blood was used as the sample instead of serum ( fig. 6 ). In this case, two different samples were taken from each patient. After deproteinL· zatipn, one sample was submitted to the kinetic assay and the other one to the hexokinase method; the coefficient of correlation obtained was lower tlian in the preceding studies. However, the slope and the y-iritercept of the regression curve were, within the 95% confidence limits. Moreover, a paired t-test showed no significant difference between the results obtained by the two methods (t = 0.84, critical t = 2.23 t 95 % confidence limits). Figures 7 and 8 illustrate that the kinetic assay can also be successfully applied to native human sera. However, it must be noted that in this instance the measured values are generally 6-11 %*higher than those obtained for the sera after deproteinization. The molecular basis for this obvious decrease of serum glucose concentration on deproteinization is still under investigation. glucose assay according to Trinder. These drugs were shown to cause a significant decrease in glucose values measured by the end-point procedure, if they had been added in vitro to human sera. Only small and almost negligible effects, however, were observed in the corresponding in vivo experiments.
When examining the in vitro influence of the above drugs on the kinetic assay, we obtained results like those shown in figures 9 and 10 2 ). One important observ ation to make here is that the kinetic approach is to a much less subject to drug interferences than the manual end^point procedure or the AutoAnalyzer I procedure. Differences in the velocity of the competitive reactions between substrates and drugs must be the reason for this effect. The data suggest that there is no in vivo drug interference with the kinetic method. Manual end-point method (I). AutoAnalyzer I method (II). GEMSAEC method, sera deproteinized with uranyl acetate (III). GEMSAEC method, native sera (IV).
Tab. 3. Analytical recovery of glucose added to lipemic human sera by use of GEMSAEC method. To study the influence of colored blood constituents, such as bilirubin or hemoglobin on the kinetic assay, we added different amounts of these substances to a human serum pool and measured the glucose concentration without deproteinization of the samples. The results obtained make it obvious (tab. 2) that these substances do not cause any interference in the assay. In addition, no interference was found from lipemia. This is illustrated by the result of analytical recovery studies from lipemic human sera supplemented with known quantities of pure glucose (tab. 3). 
Conclusions
OUT data show that the kinetic method described here is more specific than the corresponding manual end-point procedure or the AutoAnalyzer I procedure. Also, it affords a higher sample through-put because of shorter analysis time. Since the determination of a sample blank can be omitted the suggested method is convenient and reagent costs are low.
